Role of proteoglycans and glycosaminoglycans in the pathogenesis of Alzheimer's disease and related disorders: Amyloidogenesis and therapeutic strategies—A review
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The extracellular accumulation of amyloid β proteins (Aβs) in neuritic plaques is one of the hallmarks of Alzheimer's disease (AD). The binding of Aβs to extracellular membranes (ECMs) is a critical step in developing AD. Aβs bind to many biomolecules, including lipids, proteins, and proteoglycans (PGs). PGs play several roles in amyloid formation, including promoting the aggregation of Aβs into insoluble amyloid fibrils, which contributes to the increased neurotoxicity of Aβs. Although Aβs readily self‐aggregate to form amyloid fibrils in vitro, their binding to PGs and heparin enhances amyloid aggregation and fibril formation. The sulfate moiety in glycosaminoglycans (GAGs), the carbohydrate portion of PGs, is necessary for the formation of amyloid fibrils; no fibrils are observed in the presence of hyaluronic acid (HA), a nonsulfated GAG. PGs and Aβs are known to colocalize in senile plaques (SPs) and neurofibrillary tangles (NFTs) in the AD brain. The binding site of PGs to Aβs has been identified in the 13–16‐amino‐acid region (His‐His‐Gln‐Lys) of Aβs and represents a unique target site for inhibition of amyloid fibril formation; His13 in particular is an important residue critical for interaction with GAGs. The sulfate moieties of GAGs play a critical role in the binding to Aβs and enhance Aβ fibril formation. Low‐molecular‐weight heparins (LMWHs) can reverse the process of amyloidosis to inhibit fibril formation by blocking the formation of β‐plated structures, suggesting a possible therapeutic approach using LMWHs to interfere with the interaction between PGs and Aβs and to arrest or prevent amyloidogenesis. © 2010 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
Order Out of Chaos: Assembly of Ligand Binding Sites in Heparan Sulfate
Esko, J. D., & Selleck, S. B. (2002) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.71.110601.135458 · Cited by 1,495
Alzheimer's Disease and Parkinson's Disease
Nussbaum, R. L., & Ellis, C. E. (2003) · New England Journal of Medicine · doi:10.1056/nejm2003ra020003 · Cited by 1,351
Cited by
The Amyloid Beta Peptide: A Chemist’s Perspective. Role in Alzheimer’s and Fibrillization
Hamley, I. W. (2012) · Chemical Reviews · doi:10.1021/cr3000994 · Cited by 882
Physicochemical Properties of Cells and Their Effects on Intrinsically Disordered Proteins (IDPs)
Theillet, F.-X., Binolfi, A., Frembgen-Kesner, T., Hingorani, K., Sarkar, M., Kyne, C., Li, C., Crowley, P. B., Gierasch, L., Pielak, G. J., et al. (2014) · Chemical Reviews · doi:10.1021/cr400695p · Cited by 503
Pharmacology of Heparin and Related Drugs
Mulloy, B., Hogwood, J., Gray, E., Lever, R., & Page, C. P. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011247 · Cited by 341
Sulfation of Glycosaminoglycans and Its Implications in Human Health and Disorders
Soares da Costa, D., Reis, R. L., & Pashkuleva, I. (2017) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071516-044610 · Cited by 324
Sugar‐coated sperm: Unraveling the functions of the mammalian sperm glycocalyx
Tecle, E., & Gagneux, P. (2015) · Molecular Reproduction and Development · doi:10.1002/mrd.22500 · Cited by 190
Morawski, M., Brückner, G., Jäger, C., Seeger, G., Matthews, R. T., & Arendt, T. (2012) · Brain Pathology · doi:10.1111/j.1750-3639.2011.00557.x · Cited by 157
Role of the Lipid Membrane and Membrane Proteins in Tau Pathology
Bok, E., Leem, E., Lee, B.-R., Lee, J. M., Yoo, C. J., Lee, E. M., & Kim, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.653815 · Cited by 61
The “Loss” of Perineuronal Nets in Alzheimer's Disease: Missing or Hiding in Plain Sight?
Scarlett, J. M., Hu, S. J., & Alonge, K. M. (2022) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2022.896400 · Cited by 61
Circadian control of heparan sulfate levels times phagocytosis of amyloid beta aggregates
Clark, G. T., Yu, Y., Urban, C. A., Fu, G., Wang, C., Zhang, F., Linhardt, R. J., & Hurley, J. M. (2022) · PLOS Genetics · doi:10.1371/journal.pgen.1009994 · Cited by 31
“PGs are structurally diverse macromolecules that participate in a wide range of biological functions such as modulation of inflammation, extracellular matrix (ECM) assembly and remodeling, tissue repair, and ligand-receptor interactions [46,47].”
BackgroundChemistry and Function of Glycosaminoglycans in the Nervous System
Schwartz, N. B., & Domowicz, M. S. (2014) · Advances in Neurobiology · doi:10.1007/978-1-4939-1154-7_5 · Cited by 25
Molecular Networks and Key Regulators of the Dysregulated Neuronal System in Alzheimer’s Disease
Wang, M., Li, A., Sekiya, M., Beckmann, N. D., Quan, X., Schrode, N., Fernando, M. B., Yu, A., Zhu, L., Cao, J., et al. (2019) · doi:10.1101/788323 · Cited by 6
Metadata
- Authors
- Ariga, T., Miyatake, T., & Yu, R. K.
- Venue
- Journal of Neuroscience Research
- Publisher
- Wiley
- Published
- 2010-04-05
- Volume
- 88
- Issue
- 11
- Pages
- 2303-2315
- ISSN
- 0360-4012 (ISSN-L)
- 1097-4547
- OpenAlex
- W2118555707
- Cited by
- 127
- References
- 3
- FWCI
- 4.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.